Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1

NCT05199376 | Recruiting

• 1 other identifier: ET21-198
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease affecting chromosome 17. It is manifested by a neurogenic tumor proliferation that forms cutaneous, subcutaneous or deep neurofibromas. Neurofibromas can cause functional discomfort, neurogenic pain that is difficult to treat, and severe cosmetic disorders. Treatment is essentially surgical. It is sometimes a heavy invasive surgery with complicated postoperative follow-up and significant scarring on the aesthetic level. Currently, no systemic treatment has proven its effectiveness in this pathology. Percutaneous cryotherapy is a cold thermoablation procedure using fine 17 G needles introduced into the lesion after targeting by imaging. This technique is used in the treatment of soft tissue tumors and desmoid tumors. The treatment of neurofibromas with percutaneous cryotherapy is not well known. Encouraging results (unpublished) have been observed in patients with NF1 treated with cryotherapy at the Léon Bérard Center. The beneficial effect was observed in terms of quality of life (in particular, pain) as well as a decrease in tumor size. On the basis of this first experience, it appears important to corroborate these preliminary results by a prospective study allowing the use of this technique to treat patients with unresectable or resectable neurofibromas but with mutilating surgery in a NF1 context.

Conditions

Neurofibroma; Neurofibroma, Plexiform

Outcome Measures

Primary Outcomes (1)

• To evaluate the impact of percutaneous cryotherapy on physical health-related quality of life (in patients with inoperable (or operable with mutilating surgery) neurofibroma.

  Rate of patients with clinically significant improvement in physical health-related quality of life. A patient will be considered successful if an increase of at least 3 points on the global physical score from the SF-36 questionnaire is observed at least once between baseline and 12 months after cryotherapy.

  12 months after cryotherapy

Secondary Outcomes (9)

• To assess each quality of life dimension of the Short Form-36 (SF-36) questionnaire;

  At baseline, at Month1 post cryotherapy ; Month 3 post cryotherapy; Month 6 post cryotherapy, Month 9 post cryotherapy, Month 12 post cryotherapy, Month 18 post cryotherapy and Month 24 post post cryotherapy ;

• To evaluate the tumor response

  Month 3, Month 6, Month 9, Month 12, Month 18 , and Month 24 after cryotherapy

• To evaluate the functional discomfort

  At baseline, Month 1; Month 3; Month 6, Month 9, Month12, Month18 and Month 24 post cryotherapy

• To evaluate the patients' pain

  At baseline, Month 1; Month 3; Month 6, Month 9, Month 12, Month 18 and Month 24 post cryotherapy

• To evaluate the safety of percutaneous cryotherapy

  From cryotherapy to 24 months after cryotherapy

Study Arms (1)

Percutaneous cryotherapy

EXPERIMENTAL

Cryoablation of the tumor

Device: Cryotherapy

Interventions

Cryotherapy DEVICE

The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.

Percutaneous cryotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years;
• Patient with neurofibromatosis type 1 according to NIH criteria ;
• Patient with a benign neurofibromatous lesion that is painful and/or generates functional discomfort and is unresectable or with unacceptable scarring ;
• Adequate coagulation test with normals values (as judged by the investigator);
• Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment
• Covered by a medical insurance;

You may not qualify if:

• Patient treated with concomitant chemotherapy and/or targeted therapies ;
• Any contraindication to a percutaneous cryotherapy procedure, including the need for ice formation within 1 cm of the spinal cord, brain or other critical nerve structures, bowel or bladder (unless active or passive thermal protective maneuvers are performed);
• Patient with malignant neurofibroma or MPNST ; CT scan without abnormality and if tumor presents a max SUV T/F\>1.5 ratio, targeted biopsy is required to confirm benign or malignant histology.
• Patient with neurofibroma in areas at risk for neurological sequelae;
• Patient with cold urticaria with history of angioedema;
• Any cognitive impairment or condition that may limit the use of numerical scales and quality of life questionnaires;
• Patient for whom follow-up does not seem feasible even in the short term;
• Participation in another clinical trial that may interfere with the evaluation of the primary endpoint;
• Patient under tutorshio, curatorship or deprived of liberty;
• Pregnant or breast-feeding woman;
• Any contraindication to the performance of an MRI
• Patient with dysplastic neurofibroma

Sponsors & Collaborators

• Centre Leon Berard: lead

Study Sites (1)

Centre Leon Berard

Lyon, 69373, France

RECRUITING

MeSH Terms

Conditions

Neurofibroma; Neurofibroma, Plexiform

Interventions

Cryotherapy

Condition Hierarchy (Ancestors)

Nerve Sheath Neoplasms; Neoplasms, Nerve Tissue; Neoplasms by Histologic Type; Neoplasms; Peripheral Nervous System Neoplasms; Nervous System Neoplasms; Nervous System Diseases; Peripheral Nervous System Diseases; Neuromuscular Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Central Study Contacts

Patrick COMBEMALE, MD

CONTACT

+33478785996; patrick.combemale@lyon.unicancer.fr

Amine BOUHAMAMA, MD

CONTACT

amine.bouhamama@lyon.unicancer.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 21, 2021
• First Posted: January 20, 2022
• Study Start: February 14, 2022
• Primary Completion: February 7, 2026
• Study Completion (Estimated): February 7, 2027
• Last Updated: February 9, 2024

Record last verified: 2024-02

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)